Listen: The Surprising Power of Pushback When Health Insurance Won’t Pay
Being denied insurance coverage can be both confusing and, at times, enraging. But mounting a…
Listen: The Surprising Power of Pushback When Health Insurance Won’t Pay
Being denied insurance coverage can be both confusing and, at times, enraging. But mounting a skillful challenge can turn a “no” into “yes.” From confusing policy language to coding errors to shifting insurer rules, a new episode of NPR’s “Life Kit” podcast explores why denials happen and how to avoid common pitfalls. KFF Health News…
Kennedy’s Take on Vaccine Science Fractures Cohesive National Public Health Strategies
Health and Human Services Secretary Robert F. Kennedy Jr. has had a busy few months. He fired the director of the Centers for Disease Control and Prevention, purged the agency’s vaccine advisory committee, and included among the group’s new members appointees who espouse anti-vaccine views. The leadership upheavals, which he says will restore trust in…
Exactech Will Pay $8M To Settle Lawsuits Over Defective Knee Implant Parts
Medical device manufacturer Exactech has agreed to pay $8 million to settle allegations that it concealed defects in a popular line of artificial knee implants, which have been blamed for thousands of patient injuries in lawsuits. The settlement resolves two whistleblower lawsuits alleging the Florida company violated the federal False Claims Act by billing government…
AI in Healthcare: Investors’ Green and Red Flags Among Startups
During a panel discussion at the MedCity INVEST Digital Health conference, investors shared what they’re looking for from AI startups and what their red flags are. The post AI in Healthcare: Investors’ Green and Red Flags Among Startups appeared first on MedCity News.
KFF Health News’ ‘What the Health?’: Ousted CDC Officials Clap Back at RFK Jr.
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
KFF Health News’ ‘What the Health?’: Ousted CDC Officials Clap Back at RFK Jr.
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
KFF Health News’ ‘What the Health?’: Ousted CDC Officials Clap Back at RFK Jr.
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
KFF Health News’ ‘What the Health?’: Ousted CDC Officials Clap Back at RFK Jr.
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
KFF Health News’ ‘What the Health?’: Ousted CDC Officials Clap Back at RFK Jr.
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition
Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic…
